In Japan, we are actively engaged in discussions with our partner, Japan Biotechno Pharma, and regulators regarding the pending new drug application for TPOXX to treat smallpox, mpox, cowpox, and ...
The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in ...